Analysts Anticipate 10% Upside For ESGU
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 09 2025
0mins
Should l Buy CVS?
Source: NASDAQ.COM
ETF Analyst Target Prices: The iShares ESG Aware MSCI USA ETF (ESGU) has an implied analyst target price of $144.68, indicating a potential upside of 10.29% from its current trading price of $131.18. Notable underlying holdings with significant upside include ONEOK Inc, CVS Health Corporation, and Targa Resources Corp.
Investor Considerations: Analysts' target prices may reflect optimism about future stock performance, but investors should conduct further research to determine if these targets are justified or overly optimistic based on recent developments in the companies and their industries.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CVS
Wall Street analysts forecast CVS stock price to rise
17 Analyst Rating
16 Buy
1 Hold
0 Sell
Strong Buy
Current: 82.010
Low
91.00
Averages
96.71
High
105.00
Current: 82.010
Low
91.00
Averages
96.71
High
105.00
About CVS
CVS Health Corporation is a health solutions company. The Company's segments include Health Care Benefits, Health Services, Pharmacy & Consumer Wellness and Corporate/Other. The Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, PDPs and Medicaid health care management services. The Health Services segment provides a full range of pharmacy benefit management (PBM) solutions through its CVS Caremark operations and delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its CVS Pharmacy retail locations and, through its infusion operations, provides ancillary pharmacy services including pharmacy patient care programs, and vaccination administration, and sells a wide assortment of health and wellness products and general merchandise.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CVS Health Q1 Earnings Preview: Focus on Stabilization
- Earnings Expectations: CVS Health is set to report Q1 earnings on May 6, with consensus estimates predicting an EPS of $2.21, down 1.8% year-over-year, and revenue of $95.02 billion, up 0.4% year-over-year, indicating modest top-line growth but ongoing profitability pressures.
- Estimate Revisions: Recent revisions show 6 upward and 11 downward adjustments for EPS, and 4 upward versus 8 downward for revenue, reflecting increased uncertainty regarding near-term performance, although CVS has historically beaten estimates 75% of the time over the past two years.
- Operational Optimization: CVS's Aetna insurance unit plans to align 5-10 prior authorization categories with cross-payer standards by 2026, representing about 40% of volume, aimed at enhancing operational efficiency and improving cost control.
- Policy Environment Impact: Proposed healthcare reforms by the Trump administration could reshape the insurance landscape, while a 2.48% increase in Medicare Advantage payments for 2027 offers some margin support, albeit at a slower pace than previous years; CVS expects adjusted EPS for 2026 to be between $7.00 and $7.20, aligning with market expectations.
See More
Markets Hit New Highs, AI Infrastructure Leads the Charge
- Market Performance: On Tuesday, markets continued to rise without new escalations in the Middle East conflict, with West Texas Intermediate crude down about 4% and the benchmark 10-year Treasury yield slightly lower, indicating increased investor confidence in the market.
- Tech Stocks Lead: Chipmakers like Intel, SanDisk, and Micron saw double-digit percentage gains, driving a strong overall performance for technology stocks, with Amazon, Broadcom, Alphabet, and Qnity hitting new 52-week highs, reflecting robust performance in AI-related stocks.
- Strong Earnings Boost Materials: The materials sector emerged as the top performer in the S&P 500, with DuPont being the biggest mover due to its strong earnings report, highlighting investor confidence and interest in the materials industry.
- Robotic Surgery System Progress: Johnson & Johnson announced that its Ottava robotic surgery system achieved primary endpoints in clinical studies for Roux-en-Y gastric bypass procedures, which is expected to support FDA approval for multiple upper abdominal surgeries, further solidifying its position in the robotic surgery market.
See More
CVS Health Corp Announces Updates to Formulary to Increase Biosimilar Utilization Starting July 1, 2026
CVS Health Announcement: CVS Health has announced updates to its formularies aimed at expanding the use of biosimilars.
Effective Date: These changes will take effect on July 1, 2026.
See More
Health Insurers Show Strong Q1 Performance Amid Cost Challenges
- Strong Q1 Results: Major health insurers like UnitedHealth, Elevance, Cigna, and Humana exceeded expectations, boosting investor sentiment despite rising medical costs, reflecting effective strategies in pricing and cost control.
- Increased Medical Reserves: Analysts noted that insurers have strengthened medical reserves, providing a cushion for future claims, a strategy that could imply positive earnings implications for 2026, although the real data from Q2 remains crucial.
- Market Adjustment Strategies: Companies have successfully reduced medical loss ratios by exiting unprofitable markets and adjusting pricing and benefits of medical plans, demonstrating effective responses to increased demand for medical services post-pandemic, thereby enhancing market competitiveness.
- Critical Future Outlook: The second quarter will serve as a true test for insurers, as more claims data becomes available, investors will closely monitor medical loss ratios and changes in full-year outlooks to assess whether companies can sustain current growth momentum.
See More
Yeztugo Injection Faces Insurance Hurdles Despite Initial Uptake
- Market Acceptance: Since its June launch, Yeztugo has seen usage climb to nearly 75 patients, significantly lower than the expected 700 PrEP patients, indicating a lack of interest among patients that hampers Gilead's market expansion strategy.
- Insurance Coverage Issues: While Gilead claims over 90% of insurers cover Yeztugo, many patients face injection costs exceeding $14,000 and insurance denials, leading them to opt for cheaper daily medications, which impacts sales growth.
- Prescription Data Comparison: In the first quarter, over 9,000 prescriptions were written for Yeztugo, compared to 461,000 for Descovy, highlighting a preference for traditional daily medications that limits Yeztugo's market share.
- Future Sales Expectations: Analysts estimate that Yeztugo's annual sales could exceed $5 billion by 2032, although current insurance coverage and patient acceptance issues may hinder the achievement of this target.
See More
Amazon Launches Supply Chain Services, Disrupting Logistics Industry
- New Business Launch: Amazon announced the launch of Amazon Supply Chain Services (ASCS), opening its logistics network to external business customers, marking its direct competition in the logistics sector and potentially pressuring traditional delivery companies.
- Diverse Customer Base: Initial customers include Procter & Gamble, 3M, Lands' End, and American Eagle, which utilize Amazon's logistics services for raw material transportation and inventory unification, showcasing Amazon's potential in supply chain management.
- Large Market Size: The global third-party logistics services market is valued at $1.3 trillion, indicating that Amazon does not need to capture a significant market share to impact its overall business, highlighting the strategic significance of its market entry.
- Complex Competitive Outlook: While Amazon has robust infrastructure, historical precedents suggest that its threat to supermarkets and pharmacy sectors was exaggerated, indicating that its future success in logistics may still require time to validate.
See More
CVS Health Q1 Earnings Preview: Focus on Stabilization
- Earnings Expectations: CVS Health is set to report Q1 earnings on May 6, with consensus estimates predicting an EPS of $2.21, down 1.8% year-over-year, and revenue of $95.02 billion, up 0.4% year-over-year, indicating modest top-line growth but ongoing profitability pressures.
- Estimate Revisions: Recent revisions show 6 upward and 11 downward adjustments for EPS, and 4 upward versus 8 downward for revenue, reflecting increased uncertainty regarding near-term performance, although CVS has historically beaten estimates 75% of the time over the past two years.
- Operational Optimization: CVS's Aetna insurance unit plans to align 5-10 prior authorization categories with cross-payer standards by 2026, representing about 40% of volume, aimed at enhancing operational efficiency and improving cost control.
- Policy Environment Impact: Proposed healthcare reforms by the Trump administration could reshape the insurance landscape, while a 2.48% increase in Medicare Advantage payments for 2027 offers some margin support, albeit at a slower pace than previous years; CVS expects adjusted EPS for 2026 to be between $7.00 and $7.20, aligning with market expectations.
See More
Markets Hit New Highs, AI Infrastructure Leads the Charge
- Market Performance: On Tuesday, markets continued to rise without new escalations in the Middle East conflict, with West Texas Intermediate crude down about 4% and the benchmark 10-year Treasury yield slightly lower, indicating increased investor confidence in the market.
- Tech Stocks Lead: Chipmakers like Intel, SanDisk, and Micron saw double-digit percentage gains, driving a strong overall performance for technology stocks, with Amazon, Broadcom, Alphabet, and Qnity hitting new 52-week highs, reflecting robust performance in AI-related stocks.
- Strong Earnings Boost Materials: The materials sector emerged as the top performer in the S&P 500, with DuPont being the biggest mover due to its strong earnings report, highlighting investor confidence and interest in the materials industry.
- Robotic Surgery System Progress: Johnson & Johnson announced that its Ottava robotic surgery system achieved primary endpoints in clinical studies for Roux-en-Y gastric bypass procedures, which is expected to support FDA approval for multiple upper abdominal surgeries, further solidifying its position in the robotic surgery market.
See More
CVS Health Corp Announces Updates to Formulary to Increase Biosimilar Utilization Starting July 1, 2026
CVS Health Announcement: CVS Health has announced updates to its formularies aimed at expanding the use of biosimilars.
Effective Date: These changes will take effect on July 1, 2026.
See More
Health Insurers Show Strong Q1 Performance Amid Cost Challenges
- Strong Q1 Results: Major health insurers like UnitedHealth, Elevance, Cigna, and Humana exceeded expectations, boosting investor sentiment despite rising medical costs, reflecting effective strategies in pricing and cost control.
- Increased Medical Reserves: Analysts noted that insurers have strengthened medical reserves, providing a cushion for future claims, a strategy that could imply positive earnings implications for 2026, although the real data from Q2 remains crucial.
- Market Adjustment Strategies: Companies have successfully reduced medical loss ratios by exiting unprofitable markets and adjusting pricing and benefits of medical plans, demonstrating effective responses to increased demand for medical services post-pandemic, thereby enhancing market competitiveness.
- Critical Future Outlook: The second quarter will serve as a true test for insurers, as more claims data becomes available, investors will closely monitor medical loss ratios and changes in full-year outlooks to assess whether companies can sustain current growth momentum.
See More
Yeztugo Injection Faces Insurance Hurdles Despite Initial Uptake
- Market Acceptance: Since its June launch, Yeztugo has seen usage climb to nearly 75 patients, significantly lower than the expected 700 PrEP patients, indicating a lack of interest among patients that hampers Gilead's market expansion strategy.
- Insurance Coverage Issues: While Gilead claims over 90% of insurers cover Yeztugo, many patients face injection costs exceeding $14,000 and insurance denials, leading them to opt for cheaper daily medications, which impacts sales growth.
- Prescription Data Comparison: In the first quarter, over 9,000 prescriptions were written for Yeztugo, compared to 461,000 for Descovy, highlighting a preference for traditional daily medications that limits Yeztugo's market share.
- Future Sales Expectations: Analysts estimate that Yeztugo's annual sales could exceed $5 billion by 2032, although current insurance coverage and patient acceptance issues may hinder the achievement of this target.
See More
Amazon Launches Supply Chain Services, Disrupting Logistics Industry
- New Business Launch: Amazon announced the launch of Amazon Supply Chain Services (ASCS), opening its logistics network to external business customers, marking its direct competition in the logistics sector and potentially pressuring traditional delivery companies.
- Diverse Customer Base: Initial customers include Procter & Gamble, 3M, Lands' End, and American Eagle, which utilize Amazon's logistics services for raw material transportation and inventory unification, showcasing Amazon's potential in supply chain management.
- Large Market Size: The global third-party logistics services market is valued at $1.3 trillion, indicating that Amazon does not need to capture a significant market share to impact its overall business, highlighting the strategic significance of its market entry.
- Complex Competitive Outlook: While Amazon has robust infrastructure, historical precedents suggest that its threat to supermarkets and pharmacy sectors was exaggerated, indicating that its future success in logistics may still require time to validate.
See More
